PATENT CLAIM ANALYSIS

Application Number: 15771941
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "037000"]

Abstract:
This invention concerns the use of mefloquine in relation to  Mycobacterium tuberculosis . This invention also concerns the combination of mefloquine with drugs used in first and second choice treatment of tuberculosis, achieving a reduction in the treatment period of tuberculosis (TB) and the treatment of multi-drug resistant tuberculosis (MDR-TB).

Claim (Index 3):
Pharmaceutical composition in accordance with  claim 1  characterized by the fact that excipients are selected from the group consisting of microcrystalline cellulose, lactose, crospovidone, corn starch, amino calcium alginate, poloxamer (polyoxyethylene-polyoxypropylene copolymer), talc, magnesium stearate, sodium lauryl sulfate, calcium stearate, sodium carboxymethylcellulose, magnesium carbonate, carnauba wax, colophony, white beeswax, paraffin, sugar coating, acacia, gelatin, kaolin, titanium dioxide (E171), colloidal silicon dioxide, polyvinylpyrrolidone K30, sucrose, Sunset Yellow (E110).

Metadata:
- Claim Count in Document: 7.0
- Percentile: 91.0
- Lexical Diversity: 1.64706
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['10844992', '15546680', '15409911', '14112720', '14816377']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8013278792050473
- 35 USC 102 Novelty (BERT): 0.5115791732290467
- Combined Prediction Score: 0.7723530086074473
- Mean Citation Score: 244.150188
- Max Citation Score: 269.5635
- Similarity Product: 171.91295718607304

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test